For the first time, adults 60 and older are eligible to receive a vaccine against the respiratory syncytial virus, or RSV. Although many people may have not heard of RSV, it’s worth knowing that ...

Newark, New Castle, USA, June 21, 2023 (GLOBE NEWSWIRE) -- A recent report by Growth Plus Reports estimated the global respiratory syncytial virus (RSV) therapeutics market to be worth US$ 1.84 ...

Cases of respiratory syncytial virus, known as RSV, have surged, the flu season has come early, and covid-19 cases are beginning to rise. The U.S. Centers for Disease Control and Prevention ...

L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference ...

And for the last few months, patients with a different malady — respiratory syncytial virus, known as RSV — have been overwhelming hospitals. Public health officials warn that come winter ...

A quadruple whammy of viruses – flu, COVID, norovirus, and respiratory syncytial virus, or RSV – is hitting the U.S. as the year comes to a close. The Centers for Disease Control and ...

Many adults ages 60 and up will be eligible for three vaccines this fall -- a COVID booster, the flu shot, and the new respiratory syncytial virus (RSV) vaccine-- so the big question is ...

Last winter, you might have seen the headlines about rising hospitalizations from respiratory syncytial virus, or RSV. Healthcare providers now have tools to help prevent lower respiratory tract ...

Share on Pinterest Johner Images/Getty Images Respiratory syncytial virus (RSV) is a virus that leads to a mild infection. It causes symptoms that are very similar to the common cold. RSV lasts ...